202 related articles for article (PubMed ID: 27057826)
1. Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature.
Di Lorenzo G; Pagliuca M; Perillo T; Benincasa A; Bosso D; De Placido S; Buonerba C
Medicine (Baltimore); 2016 Apr; 95(14):e2754. PubMed ID: 27057826
[TBL] [Abstract][Full Text] [Related]
2. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
Thibault C; Eymard JC; Birtle A; Krainer M; Baciarello G; Fléchon A; Le Moulec S; Spaeth D; Laguerre B; Caffo O; Deville JL; Beuzeboc P; Hasbini A; Gross-Goupil M; Helissey C; Bennamoun M; Hardy-Bessard AC; Oudard S
Eur J Cancer; 2018 Jul; 97():41-48. PubMed ID: 29636272
[TBL] [Abstract][Full Text] [Related]
4. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
5. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
[TBL] [Abstract][Full Text] [Related]
6. Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel - A Final Analysis of the Prosty II Trial.
Kellokumpu-Lehtinen PL; Marttila T; Jekunen A; Hervonen P; Klintrup K; Kataja V; Utriainen T; Luukkaa M; Leskinen M; Pulkkanen K; Kautio AL; Huttunen T
Anticancer Res; 2020 Dec; 40(12):6915-6921. PubMed ID: 33288585
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.
Oudard S; Kramer G; Caffo O; Creppy L; Loriot Y; Hansen S; Holmberg M; Rolland F; Machiels JP; Krainer M
BJU Int; 2015 May; 115(5):744-52. PubMed ID: 24947139
[TBL] [Abstract][Full Text] [Related]
9. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study.
Byeon S; Kim H; Kim J; Kwon M; Hur JY; Jeon HG; Jeon SS; Lee HM; Park SH
Investig Clin Urol; 2020 Nov; 61(6):588-593. PubMed ID: 32985144
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel rechallenge in metastatic castration-resistant prostate cancer: any place in the modern treatment scenario? An intention to treat evaluation.
Bracarda S; Caserta C; Galli L; Carlini P; Pastina I; Sisani M; Scali S; Hamzaj A; Derosa L; Felici A; Rossi M; Altavilla A; Chioni A; De Angelis V
Future Oncol; 2015 Nov; 11(22):3083-90. PubMed ID: 26437324
[TBL] [Abstract][Full Text] [Related]
13. Budgetary Impact of Cabazitaxel Use After Docetaxel Treatment for Metastatic Castration-Resistant Prostate Cancer.
Flannery K; Drea E; Hudspeth L; Corman S; Gao X; Xue M; Miao R
J Manag Care Spec Pharm; 2017 Apr; 23(4):416-426. PubMed ID: 28345444
[TBL] [Abstract][Full Text] [Related]
14. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
15. Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer.
Nozawa M; Mukai H; Takahashi S; Uemura H; Kosaka T; Onozawa Y; Miyazaki J; Suzuki K; Okihara K; Arai Y; Kamba T; Kato M; Nakai Y; Furuse H; Kume H; Ide H; Kitamura H; Yokomizo A; Kimura T; Tomita Y; Ohno K; Kakehi Y
Int J Clin Oncol; 2015 Oct; 20(5):1026-34. PubMed ID: 25809824
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.
Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; Maines F; Veccia A; Galligioni E
Urol Oncol; 2015 Jun; 33(6):265.e15-21. PubMed ID: 25907622
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
Armstrong AJ; Humeniuk MS; Healy P; Szmulewitz R; Winters C; Kephart J; Harrison MR; Martinez E; Mundy K; Halabi S; George D
Prostate; 2017 Mar; 77(4):385-395. PubMed ID: 27862097
[TBL] [Abstract][Full Text] [Related]
19. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison.
Zheng H; Chen J; Qiu W; Lin S; Chen Y; Liang G; Fang Y
Biomed Res Int; 2017; 2017():3941217. PubMed ID: 29951524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
